M
Mary S. McCabe
Researcher at National Institutes of Health
Publications - 21
Citations - 1148
Mary S. McCabe is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cancer & Clinical trial. The author has an hindex of 12, co-authored 21 publications receiving 1092 citations. Previous affiliations of Mary S. McCabe include Walter Reed Army Institute of Research.
Papers
More filters
Journal ArticleDOI
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
Warren B. Sateren,Edward L. Trimble,Jeffrey Abrams,Otis W. Brawley,Nancy Breen,Leslie G. Ford,Mary S. McCabe,Richard Kaplan,M Smith,Richard Ungerleider,Michaele C. Christian +10 more
TL;DR: The number of oncologists and the presence of approved cancer programs both were significantly associated with increased accrual to clinical trials, and the highest observed accruals was in suburban counties.
Journal ArticleDOI
A Central Institutional Review Board for Multi-Institutional Trials
Michaele C. Christian,Jacquelyn Goldberg,Jack Killen,Jeffrey S. Abrams,Mary S. McCabe,Joan K Mauer,Robert E. Wittes +6 more
TL;DR: The Office of the Inspector General of the Department of Health and Human Services concluded that institutional review boards (IRBs) are now forced to review too much, too quickly, with too little expertise, and with inadequate resources.
Journal ArticleDOI
Quality of Life in Phase II Trials: a Study of Methodology and Predictive Value in Patients With Advanced Breast Cancer Treated With Paclitaxel Plus Granulocyte Colony-Stimulating Factor
Andrew D. Seidman,Rusell Portenoy,Tzy-Jyun Yao,Jean Lepore,Erik K. Mont,Jeremy S. Kortmansky,Nicole Onetto,Leigh Ren,Janice Grechko,Mohan Beltangady,Jeffrey Usakewicz,Magdalena Southrada,Collette Houston,Mary S. McCabe,Rori Salvaggio,Howard T. Thaler,Larry Norton +16 more
TL;DR: In this paper, the authors evaluated the utility of quality-of-life assessment in two phase II clinical trials of patients receiving paclitaxel (Taxol) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) as salvage therapy for metastatic breast cancer.
Journal ArticleDOI
The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06.
Michaele C. Christian,Mary S. McCabe,Edward L. Korn,Jeffrey S. Abrams,Richard Kaplan,M A Friedman +5 more
TL;DR: An audit of other participating institutions confirms the adequacy of the data on which the reanalysis of Protocol B-06 and the results after 12 years of follow-up are based.
Journal ArticleDOI
Incremental Treatment Costs in National Cancer Institute–Sponsored Clinical Trials
Dana P. Goldman,Sandra H. Berry,Mary S. McCabe,Meredith L. Kilgore,Arnold L. Potosky,Michael Schoenbaum,Matthias Schonlau,Jane C. Weeks,Richard Kaplan,José J. Escarce +9 more
TL;DR: The additional treatment costs of an open reimbursement policy for government-sponsored cancer clinical trials appear minimal and were higher for patients who died and who were in early phase studies, although these findings deserve further scrutiny.